* Integra Lifesciences Holdings Corp IART.OQ IART.O is
expected to show a fall in quarterly revenue when it reports
results on May 6 for the period ending March 31 2024
* The Princeton New Jersey-based company is expected to
report a
5.0% decrease in revenue to $361.962 million from $380.85
million a year ago, according to the mean estimate from 11
analysts, based on LSEG data.The company's guidance on February
28 2024, for the period ended March 31, was for revenue between
$360.00 million and $365.00 million.
* LSEG's mean analyst estimate for Integra Lifesciences
Holdings
Corp is for earnings of 55 cents per share. The company's EPS
guidance on February 28 2024, for the period ended March 31, was
between $0.53 and $0.57
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 6
"hold" and 3 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Integra
Lifesciences Holdings Corp is $43.50, above its last closing
price of $28.75.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 0.90 0.90 0.89 Missed -1.5
Sep. 30 2023 0.78 0.78 0.76 Missed -2.3
Jun. 30 2023 0.57 0.57 0.71 Beat 24.8
Mar. 31 2023 0.74 0.74 0.74 Met 0.4
Dec. 0.91 0.90 0.94 Beat 4.1
31 2022
Sep. 30 2022 0.71 0.72 0.86 Beat 19.5
Jun. 30 2022 0.80 0.80 0.81 Beat 1.6
Mar. 31 2022 0.68 0.68 0.74 Beat 8.8
This summary was machine generated May 3 at 13:05 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)